Genmab A-S Aktie [WKN: 565131 / ISIN: DK0010272202]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Genmab A-S

18.03.24		Completion of share buy-back program (GlobeNewswire)
15.03.24		Genmab Announces Initiation of Share Buy-Back Program (GlobeNewswire)
13.03.24		Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
13.03.24		Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
13.03.24		Passing of Genmab A/S’ Annual General Meeting (GlobeNewswire)
11.03.24		Transactions in connection with share buy-back program (GlobeNewswire)
04.03.24		Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
04.03.24		Transactions in connection with share buy-back program (GlobeNewswire)
02.03.24		Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
29.02.24		Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
27.02.24		Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
27.02.24		Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
27.02.24		U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (GlobeNewswire)
26.02.24		Transactions in connection with share buy-back program (GlobeNewswire)
23.02.24		Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
23.02.24		Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
19.02.24		Transactions in connection with share buy-back program (GlobeNewswire)
15.02.24		Notice to Convene the Annual General Meeting of Genmab A/S (GlobeNewswire)
14.02.24		Genmab Files Annual Report with the U.S. Securities and Exchange Commission (GlobeNewswire)
14.02.24		Genmab Announces Initiation of Share Buy-Back Program (GlobeNewswire)
14.02.24		Genmab Publishes 2023 Annual Report (GlobeNewswire)
02.02.24		Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer (GlobeNewswire)
25.01.24		Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
23.01.24		Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023 (GlobeNewswire)
23.01.24		Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen (GlobeNewswire)
09.01.24		TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer (GlobeNewswire)
03.01.24		Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire)
02.01.24		Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
12.12.23		Genmab to Hold 2023 R&D Update and ASH Data Review Meeting (GlobeNewswire)
09.12.23		New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL) (GlobeNewswire)
05.12.23		Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
27.11.23		Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma (GlobeNewswire)
21.11.23		Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
21.11.23		Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
09.11.23		Major Shareholder Announcement (GlobeNewswire)
09.11.23		Genmab to Present at Jefferies London Healthcare Conference (GlobeNewswire)
08.11.23		Major Shareholder Announcement (GlobeNewswire)
07.11.23		Genmab Announces Financial Results for the First Nine Months of 2023 (GlobeNewswire)
02.11.23		Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH) (GlobeNewswire)
22.10.23		TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial (GlobeNewswire)
17.10.23		Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023 (GlobeNewswire)
28.09.23		Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
25.09.23		Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) (GlobeNewswire)
25.09.23		EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Ce (GlobeNewswire)
12.09.23		Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
04.09.23		Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy (GlobeNewswire)
28.08.23		Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
15.08.23		Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
03.08.23		Genmab Announces Financial Results for the First Half of 2023 (GlobeNewswire)
28.07.23		Genmab Updates 2023 Financial Guidance (GlobeNewswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Pierer Mobility-Aktie unter Druck: KTM-Pleite - Schockstarre in der Region und bei den Zulieferern - Land OÖ signalisiert Bereitschaft Beschäftigten zu helfen

voestalpine-Aktie zieht an: Erste Group stuft Aktie von "Accumulate" auf "Buy" hoch

Rosenbauer erwartet kein Problem bei Kapitalerhöhung wegen KTM-Pleite - Rosenbauer-Aktie fester

Pierer Mobility-Aktie bricht ein: KTM steht vor Insolvenz

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	30.11.2024 20:06
Kaufwert:	EUR
	Hinzufügen Speichern